Marketing Authorisation Application for lecanemab submitted in Great Britain: BioArctic ...Middle East

PR Newswire - News
STOCKHOLM, May 22, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that they have submitted a Marketing Authorisation Application (MAA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril[1] antibody, for the treatment...

Hence then, the article about marketing authorisation application for lecanemab submitted in great britain bioarctic was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Marketing Authorisation Application for lecanemab submitted in Great Britain: BioArctic )

Apple Storegoogle play

Last updated :

Also on site :